Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

4.405 +0.045 (+1.03%)
Streaming Delayed Price Updated: 2:48 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Vir (VIR) Q2 Revenue Drops 61%
Via The Motley Fool
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Outlook For Vir Biotechnology
 
Via Benzinga
5 Analysts Have This To Say About Vir Biotechnology
 
Via Benzinga
7 Analysts Have This To Say About Vir Biotechnology
 
Via Benzinga
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
From Vir Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Where Vir Biotechnology Stands With Analysts
 
Via Benzinga
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.